Orion
44.16
EUR
-0.99 %
ORNBV
NASDAQ Helsinki
Biotechnology & Pharmaceuticals
Health Care
13,886 following
-0.99%
-1.27%
-7.29%
-5.09%
+16.98%
+12.45%
+17.89%
+20.66%
+9.31%
+293.23%
www.orion.fi/link/a9675e2f54c7457aa402ff1dc6a6b676.aspx
Orion operates in the pharmaceutical industry. The company conducts research and development of human and veterinary drugs, where the main focus is on diseases that affect the nervous system, as well as oncology and respiratory diseases. Today, the company's products are found on a global level, with the largest presence in the Nordic region and the rest of Europe. The company's head office is located in Espoo, Finland.
P/E (adj.) (24e)
19.91
EV/EBIT (adj.) (24e)
15.69
P/B (24e)
6.37
Dividend yield-% (24e)
3.74 %
Target price
47.00 EUR
Recommendation
Accumulate
Updated
30.10.2024
NASDAQ Helsinki
ORNBV
Daily low / high price
43.98 / 44.6
EUR
Market cap
6.23B EUR
Turnover
525.51K EUR
Volume
12K
Business risk
Valuation risk
Current
Previous
Analyst
Antti Siltanen
Analyst
Financial calendar
Annual report
25.02.2025
General meeting
03.04.2025
Interim report
23.04.2025
Interim report
18.07.2025
Interim report
28.10.2025
Income statement
| 2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e | 2027e | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1,078.1 | 1,041.1 | 1,340.6 | 1,189.6 | 1,483.0 | 1,531.0 | 1,805.7 | 1,752.5 |
| growth-% | 2.6 % | -3.4 % | 28.8 % | -11.3 % | 24.7 % | 3.2 % | 17.9 % | -2.9 % |
| EBITDA | 336.5 | 289.0 | 486.6 | 326.4 | 445.1 | 410.3 | 595.0 | 510.0 |
| EBIT (adj.) | 280.1 | 243.3 | 439.6 | 274.9 | 394.1 | 366.3 | 541.7 | 455.7 |
| EBIT | 280.1 | 243.3 | 439.6 | 274.9 | 394.1 | 366.3 | 541.7 | 455.7 |
| Profit before taxes | 278.3 | 242.3 | 440.3 | 271.9 | 391.1 | 364.7 | 541.2 | 456.0 |
| Net income | 219.9 | 193.8 | 349.5 | 216.8 | 311.5 | 288.1 | 427.6 | 360.3 |
| EPS (adj.) | 1.57 | 1.38 | 2.49 | 1.54 | 2.22 | 2.05 | 3.04 | 2.56 |
| growth-% | 9.9 % | -11.9 % | 80.3 % | -38.0 % | 43.7 % | -7.5 % | 48.4 % | -15.7 % |
| Dividend | 1.50 | 1.50 | 1.60 | 1.62 | 1.65 | 1.70 | 1.75 | 1.80 |
| Dividend ratio | 95.8 % | 108.7 % | 64.3 % | 105.0 % | 74.4 % | 82.9 % | 57.5 % | 70.2 % |
Profitability and return on capital
| 2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e | 2027e | |
|---|---|---|---|---|---|---|---|---|
| EBITDA-% | 31.2 % | 27.8 % | 36.3 % | 27.4 % | 30.0 % | 26.8 % | 33.0 % | 29.1 % |
| EBIT-% (adj.) | 26.0 % | 23.4 % | 32.8 % | 23.1 % | 26.6 % | 23.9 % | 30.0 % | 26.0 % |
| EBIT-% | 26.0 % | 23.4 % | 32.8 % | 23.1 % | 26.6 % | 23.9 % | 30.0 % | 26.0 % |
| ROE | 29.1 % | 26.8 % | 43.1 % | 24.1 % | 33.4 % | 28.8 % | 38.0 % | 28.2 % |
| ROI | 34.4 % | 29.5 % | 45.6 % | 24.9 % | 36.2 % | 33.4 % | 46.7 % | 35.7 % |
Valuation
| 2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e | 2027e | |
|---|---|---|---|---|---|---|---|---|
| Share price (EUR) | 40.95 | 36.66 | 49.70 | 37.50 | 44.16 | 44.16 | 44.16 | 44.16 |
| Shares | 140.5 | 140.5 | 140.5 | 140.5 | 140.5 | 140.5 | 140.5 | 140.5 |
| Market cap | 5,752.0 | 5,149.4 | 6,981.0 | 5,267.4 | 6,202.8 | 6,202.8 | 6,202.8 | 6,202.8 |
| Enterprise value | 5,566.2 | 4,960.0 | 6,862.4 | 5,360.7 | 6,184.1 | 6,139.8 | 6,030.8 | 5,880.4 |
| EV/S | 5.2 | 4.8 | 5.1 | 4.5 | 4.2 | 4.0 | 3.3 | 3.4 |
| EV/EBITDA | 16.5 | 17.2 | 14.1 | 16.4 | 13.9 | 15.0 | 10.1 | 11.5 |
| EV/EBIT (adj.) | 19.9 | 20.4 | 15.6 | 19.5 | 15.7 | 16.8 | 11.1 | 12.9 |
| EV/EBIT | 19.9 | 20.4 | 15.6 | 19.5 | 15.7 | 16.8 | 11.1 | 12.9 |
| P/E (adj.) | 26.2 | 26.6 | 20.0 | 24.3 | 19.9 | 21.5 | 14.5 | 17.2 |
| P/E | 26.2 | 26.6 | 20.0 | 24.3 | 19.9 | 21.5 | 14.5 | 17.2 |
| P/B | 7.9 | 7.2 | 7.7 | 5.9 | 6.4 | 6.0 | 5.1 | 4.7 |
| P/S | 5.3 | 4.9 | 5.2 | 4.4 | 4.2 | 4.1 | 3.4 | 3.5 |
| Dividend yield | 3.7 % | 4.1 % | 3.2 % | 4.3 % | 3.7 % | 3.9 % | 4.0 % | 4.1 % |
| Equity ratio | 65.6 % | 66.0 % | 60.4 % | 61.9 % | 66.7 % | 69.6 % | 75.4 % | 77.2 % |
| Gearing ratio | -25.4 % | -26.5 % | -13.1 % | 10.5 % | -1.9 % | -6.1 % | -14.1 % | -24.2 % |
Quarter data
| Q4/23 | 2023 | Q1/24 | Q2/24 | Q3/24 | Q4/24e | 2024e | Q1/25e | Q2/25e | |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 321.1 | 1,189.6 | 308.5 | 328.2 | 471.3 | 375.0 | 1,483.0 | ||
| EBITDA | 106.6 | 326.4 | 67.0 | 80.3 | 215.0 | 82.8 | 445.1 | 81.6 | 95.1 |
| EBIT | 92.9 | 274.9 | 56.0 | 65.8 | 202.0 | 70.3 | 394.1 | 70.6 | 84.1 |
| Profit before taxes | 92.5 | 271.9 | 54.9 | 65.1 | 201.4 | 69.7 | 391.1 | 70.6 | 84.1 |
| Net income | 75.2 | 216.8 | 43.7 | 52.0 | 160.7 | 55.1 | 311.5 | 70.6 | 84.1 |
ShowingAll content types
Orion Corporation: Managers’ transactions – Henrik Stenqvist
Orion Oyj, Q3'24
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Orion Group Interim Report January–September 2024
Inside information: Orion terminates ODM-111 development program due to narrow therapeutic window of the molecule
Orion publishes Interim Report for January–September 2024 and holds a webcast on 29 October 2024
Orion’s collaboration partner Bayer submits application for third indication of darolutamide in the EU
Orion’s near-term climate targets approved by the Science Based Targets initiative
Orion’s collaboration partner Bayer submits application to U.S. FDA for third indication of darolutamide which has become the first ever Orion-originated blockbuster
213,285 Orion Corporation A shares converted into B shares
Inside information: Orion upgrades full-year outlook for 2024
Clinical phases of drug development
Orion Corporation: Managers’ transactions – Satu Ahomäki
Orion Corporation: Managers’ transactions – Niclas Lindstedt
Orion Corporation: Managers’ transactions – Liisa Hurme
Orion Corporation: Managers’ transactions – Hao Pan
44,767 Orion Corporation A shares converted into B shares
Orion Corporation: Managers’ transactions – Satu Ahomäki
